I-Mab Announces CMO Transition, Interim Successor Named
Company Announcements

I-Mab Announces CMO Transition, Interim Successor Named

I-Mab Adr (IMAB) has released an update.

I-Mab has announced the resignation of their Chief Medical Officer Dr. John Hayslip, who is departing to pursue new opportunities and whose exit is not due to internal conflicts. In the interim, the company has engaged Dr. Louie Naumovski, a seasoned professional with over 30 years in the biopharmaceutical industry, specializing in oncology drug development. The search for a permanent successor is currently underway.

For further insights into IMAB stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskI-Mab Appoints New CEO to Drive Cancer Therapy Goals
TheFlyI-Mab names Sean Fu as permanent CEO
TheFlyInhibrx prevails in trade secret case with I-Mab
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App